Novo Nordisk launches Wegovy in India, expanding GLP-1 obesity drug market. The product competes with Eli Lilly's Mounjaro ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Deepseek AI’s scare kicked off the year, rattling faith in the “Magnificent Seven” and the broader tech space. 💵💰Don't miss ...

Novo Nordisk (NYSE: NVO) and Hims & Hers Health (NYSE: HIMS) announced they were collaborating to allow Hims & Hers to sell ...

The drug is under distribution and will be in pharmacies by end of the month, said Vikrant Shrotriya, Novo Nordisk's India ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply, and believes ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Weaver outlined her concerns with counterfeit weight-loss medication. “If there is, contaminants, allergens in it, that sort ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...